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Abstract
Background: Identifying people at higher risk of having squamous dysplasia, the precursor lesion for esophageal squamous cell carci-
noma (ESCC), would allow targetedendoscopic screening.
Methods: We used multivariate logistic regression models to predict ESCC and dysplasia as outcomes. The ESCC model was based on 
data from the Golestan Case-Control Study (total n = 871; cases = 300), and the dysplasia model was based on data from a cohort of sub-
jects from a GIclinic in Northeast Iran (total n = 724; cases = 26). In each of these analyses, we ¿t a model including all risk factors known 
in this region to be associated with ESCC. Individual risks were calculated using the linear combination of estimated regression coef¿cients 
and individual-speci¿c values for covariates. We used cross-validation to determine the area under the curve (AUC) and to ¿nd the optimal 
cut points for each of the models.
Results: The model had an area under the curve of 0.77 (95% CI: 0.74–0.80) to predict ESCC with74% sensitivity and 70.4% speci¿city for 
the optimum cut point. The area under the curve was 0.71 (95% CI: 0.64–0.79) for dysplasia diagnosis, and the classi¿cation table optimized 
at 61.5% sensitivity and 69.5% speci¿city. In this population, the positive and negative predictive values for diagnosis of dysplasia were 6.8% 
and 97.8%, respectively.
Conclusion: Our models were able to discriminate between ESCC cases and controls in about 77%, and between individuals with and 
without squamous dysplasia in about 70% of the cases. Using risk factors to predict individual risk of ESCC or squamous dysplasia still has 
limited application in clinical practice,but such models may be suitable for selecting high risk individuals in research studies, or increasing the 
pretest probability for other screening strategies. 
Introduction
E sophageal squamous cell carcinoma (ESCC) is still the most prevalent type of esophageal cancer in the world1 and the 
¿rst cause of cancer mortality and morbidity in Golestan 
Province in the Northeast of Iran.2 Despite recent advances in can-
cer care, ESCC still has a ¿ve-year survival of less than 20% in the 
U.S.3 In Golestan Province, it has an even poorer prognosis, with a 
median survival of 7 months and a ¿ve-year survival of only 3.3%.4 
Thus, it is very important to diagnose ESCC in very early stages, 
when treatments with curative intent are possible. Squamous dys-
plasia is the precursor lesion for ESCC,5 and it can be detected by 
endoscopy with Lugol’s iodine staining and biopsy of unstained 
areas.6 But endoscopic screening of all adults is not practical.  Lim-
iting this screening to a subset of individuals witha higher risk of 
squamous dysplasia, and ultimately ESCC, would reduce the clin-
ical burden and likely increase the acceptance of this screening 
method. In the past, different statistical models have been applied 
to predict the risk of cancer development in individuals, the most 
well-known of which is the Gail model for breast cancer.7 Models 
have also been developed to predict the risk of having precursor 
lesions for both esophageal squamous cell carcinoma8 and adeno-
carcinoma.9–10 The purpose of this study was to try to develop a 
statistical model using known risk factors to predict individual risk 
of squamous dysplasiaor ESCC in Northeast Iran.
Materials and Methods 
We built and tested two separate models for ESCC and squamous 
dysplasia, each using a different set of data. We used data from the 
Golestan Case-Control Study to build the ESCC model. This study 
was conducted from 2003 to 2007, and included 300 biopsy-prov-
en ESCC cases and 571 age and sex-matched neighborhood con-
trols. Details of this study and data collection have been published 
before.11  We used data from individuals visiting Atrak Clinic, a 
gastroenterology research clinic in Gonbad City, in Golestan Prov-
ince, to build the dysplasia model. Atrak Clinic was set up by the 
Digestive Disease Research Center of Tehran University of Medi-
cal Sciences in 2001, and patients complaining of GI symptoms 
are referred to it by local physicians. Between 2002 and 2007, 724 
individuals with GI symptoms visited this clinic and underwent 
video endoscopy with Lugol’s iodine staining and completed the 
same questionnaire used in the Golestan Case-Control Study.11 All 
unstained lesions were biopsied and sent for histological examina-
tion. Overall, 26 individuals with dyplastic lesions were identi¿ed 
in this group.
We used multivariate logistic regression models to predict ESCC 
and squamous dysplasia. The ESCC model was based on the case-
control data (total n = 871; cases = 300), and the dysplasia model 
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on the data from Atrak Clinic (total n = 724; cases = 26). In each 
of these we ¿rst ¿t a model including all risk factors known in 
this region to be associated with ESCC, according to previous re-
ports,11–15 and then added unintentional weight loss in the past year 
to the model. The known risk factors included: age, ethnicity, to-
bacco smoking, opium use, education, marital status, oral health, 
family history, tea temperature, and water source. We tested each 
model for goodness of ¿t using Hosmer-Lemeshow (H-L) chi 
square. The p value for this test compares the predicted and ob-
served probabilities, and a signi¿cant P value shows lack of ¿t. In 
general, the base models (without weight loss) had a better good-
ness of ¿t (H-L P = 0.13 for ESCC and P = 0.10 for dysplasia) than 
the model including weight loss (H-L P < 0.001).
Individual risks were estimated using the linear combination 
of the regression coef¿cients and individual-speci¿c values for 
covariates. A receiver operating characteristic (ROC) curve was 
drawn using the estimates obtained in this way. The area under 
the ROC curve (concordance index) determines the power of the 
model to discriminate between each randomly-selected pair of 
cases and controls, and can be between 0.5 (no discrimination bet-
ter than chance alone) to 1 (perfect discrimination).16 Classifying a 
set of outcomes, using the same observations both to ¿t the model 
and to estimate the classi¿cation error, will result in biased error-
count estimates, and the resulting validation results are over¿t.17 
To correct for this bias, we usedcross-validation:the whole dataset 
without a single observation was used to build the model and then 
based on that model, outcome probability was predictedin that sin-
gle observation;thiswas repeated this for all observations. Crossval 
macro18 for Stata Statistical Software (Release 11, StataCorp, Col-
lege Station, TX) was used to draw cross-validated ROC curve and 
calculate the area under the curve (concordance index) and its 95% 
con¿dence interval.
It is also possible to use a one-step approximation to the param-
eter estimates, as described before,19 instead of the “leave-one-out” 
cross validation. To produce a classi¿cation table comparing sen-
sitivities and speci¿cities of different prediction cutpoints for each 
model, we usedthis one-step method in Statistical Analyzing Sys-
tem release 9 (SAS Institute, Carey, NC).19 Estimates of are given 
by:
Where:
ߚመ  is the maximum likelihood estimate of the parameter vector 
based on all observations;
ߚఫ෡  is the same maximum likelihood estimate without the jth ob-
servation;
yj is 1 for an observed event and 0 otherwise;
Ȧj is the weight of the jth observation;
ߨఫෝ  is the predicted event probability based on ߚመ  ;
hjj is the hat diagonal element assuming single trial with yj event;
෡൫ߚመ൯ is the estimated covariance matrix of ߚመ   .
In the classi¿cation table, the optimal cutpoint for the model ac-
curacy was the one with the best combination of sensitivity and 
speci¿city. This point also had the same predicted probability of 
the outcome as the observed prevalence in the sample.We then 
used the sensitivity and speci¿city of this optimal point to estimate 
positive and negative predictive values of the model against differ-
ent hypothetical values for the prevalence of dysplasia in general 
population.
Results
E SCC risk prediction
The multivariate model including all known risk factors had a 
cross-validatedarea under the curve (AUC) of 0.77 (95% CI: 0.74–
0.80) to predict ESCC (Figure 1A). This means that in 77% of ran-
domly selected case-control pairs, the model will predict a higher 
probability of ESCC for the case compared to the control. The 
bias-corrected optimal point hada74.0% sensitivity and a 70.4% 
speci¿city. After adding weight loss in the past year to the model 
(Figure 1B), the AUC increased to 0.87 (95% CI: 0.85–0.89), and 
the optimal point in the classi¿cation tablehad 80.6% sensitivity 
and 82.4% speci¿city. However, the model had a poor goodness-
of-¿t statistic (H-L P < 0.001)
Dysplasia risk
The model with all known risk factors except weight loss (Fig-
ure 1C) had a cross-validated area under the curve of 0.71 (95% 
CI: 0.64–0.79), which showed little change when weight loss was 
added to the model (Figure 1D). As the ¿gure shows, the ROC 
curves were not smooth because of the relatively low prevalence 
of dysplasia (3.6%) and at the optimal cutpoint, a sensitivity of 
61.5% and a speci¿city of 69.5% were observed. Table 1 shows 
the positive and negative predictive values for this cutpoint with 
different hypothetical prevalences of dysplasia. As can be seen 
in the table, with values close to the observed prevalence in this 
sample, the positive and negative predictive values are 6.8% and 
97.8%, respectively.
Discussion
Our models were able to discriminate between ESCC cases and 
controls in about 77%, and between individuals with and without 
Prevalence of dysplasia (%) False positive rate (%) False negative rate (%) Positive predictive value (%) Negative predictive value (%)
0.02 96.5 1.1 3.5 98.9
0.04 93.2 2.2 6.8 97.8
0.06 89.9 3.4 10.1 96.6
0.08 86.8 4.6 13.2 95.4
0.1 83.7 5.8 16.3 94.2
0.2 69.5 12.1 30.5 87.9
0.3 57.1 19.1 42.9 80.9
0.4 46.1 26.9 53.9 73.1
The optimal sensitivity (61.9%) and speci¿city (69.9%) for the dysplasia prediction model was used.
Table 1. The effect of different hypothetical prevalences for dysplasia on positive and negative predictive values of the regression model.
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squamous dysplasiain about 70% of the cases. The model, how-
ever, had only a 6.8% positive predictive value for diagnosing dys-
plasia, due to the low prevalence of this lesion. 
Our results were better than a previous study done in another high 
risk area in China.8 In that study, Wei et al. observed a sensitivity of 
57% and a speci¿city of 54% for predicting squamous dysplasia, 
in spite of the fact that many components of the model were sig-
ni¿cantly associated with the risk of dysplasia. The area under the 
curve was 0.58 in their study without using anyvalidation method; 
the area under the curve was already very low and using any vali-
dation would have decreased it even further.8 We found better sen-
sitivity and speci¿city, and a higher area under the curve despite 
using cross validation (even the lower bound of the con¿dence 
interval in our study was higher than 0.58). The cross-validation 
method tests the model in individuals other than the ones used for 
model building, and thus gives a more realistic estimate of the dis-
criminating power of the model.
Studies using questionnaire data and symptoms to predict 
esophageal adenocarcinoma have had similar results. Models us-
ing symptoms and individual characteristics for the diagnosis of 
Barrett’s esophagus, a precursor lesion of esophageal adenocarci-
noma had an AUC of 0.7210 and 0.76.9 One big difference is that 
Barrett’s esophagus is closely related to gastroesophageal reÀux 
disease (GERD), and thus GERD symptoms can be used in the 
model, while dysplasia is rarely symptomatic.
In validation studies, a model may have a good ability to dis-
criminate between cases and controls, but may not be able to cor-
rectly predict the probability of the event.20 Calibration refers to 
the agreement between predicted probabilities and the observed 
proportions.16 In our data, the base models (without weight loss) 
showed good calibration according to the Hosmer-Lemeshow sta-
tistic. Interestingly, although the ESCC model with weight loss had 
the highest area under the curve, it had a poor ¿t. This model has 
also little application, since weight loss develops during the symp-
tomatic stage of ESCC when endoscopy is strongly indicated and 
risk screening is no more useful.
One of the limitations in our study was the small number of dys-
plastic cases, which has led to wider con¿dence intervals for the 
dysplasia model compared with ESCC models. On the other hand, 
although the ESCC model had more cases, the prediction of ESCC 
is not the main purpose of risk screening. The ESCC cases in this 
series have advanced symptomatic disease, and by the time ESCC 
has reached this stage, it is usually too late for any intervention. 
Unlike high-risk areas in China, where about 30% of the general 
population have squamous dysplasia,8 in our sample this rate was 
only about 4%. Disease prevalence determines posttest probabili-
ties in different populations,21 so even with the best estimates of 
accuracy, given this low prevalence, the predictive values will be 
so low that the use of a risk factor model for individual risk strati¿-
cation is not advisable. With 62% sensitivity and a70% speci¿city, 
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Figure 1. Receiver operating characteristic (ROC) curves comparing the sensitivities and speci¿cities of models to predict esophageal squamous cell 
carcinoma (ESCC) and squamous dysplasia in Golestan Province. A) ESCC risk factors, B) ESCC risk factors with weight loss, C) dysplasia risk factors, 
D) dysplasia risk factors with weight loss.
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about 93% of positive cases will be false positives, and the posi-
tive predictive value (PPV) for dysplasia will be only around 7%. 
This implies that, on average, out of 100 endoscopies performed 
in high-risk individuals (according to the model), only 7 will have 
dysplasia, while this number is 4 in a randomly-selected sample of 
the general population. On the other hand, if the prevalence of dys-
plasia were similar to China, we would have a positive predictive 
value of 42.9%, which would make it more suitable as an initial 
selection step for endoscopic screening. The reasons for such a low 
prevalence of dysplasia, despite the high incidence of ESCC, re-
mains to be determined and may range from differences in ESCC 
pathogenesis between the two populations (e.g., faster progression 
from dysplasia to ESCC), to technical differences in the screening 
methods used.
Lack of reproducibility is a general problem with many risk mod-
els.10 Different populations may have different risk factors for the 
disease (e.g., the risk factors used in China were different from 
those used in Iran to build the prediction model). Also, the stud-
ies validating these models usually use internal validation (like the 
cross-validation used in our study), rather than true external vali-
dation (which needs testing the model on new data collected from 
another population).22 Besides, many clinicians are reluctant to use 
statistical models for risk assessment and strati¿cation.21 These 
models, however, may prove useful in research studies, where a 
researcher is interested in selecting a group at higher potential risk 
for developing the precursorlesion and ultimately cancer.
The latest cancer registry data from Golestan show a very high 
incidence of ESCC, especially in the population above 50 years 
of age.23 This high incidence, together with the poor prognosis of 
ESCC in this region, underlines the importance of ¿nding alter-
native strategies for early detection. Sponge balloon cytology has 
recently been shown to be effective for detection of patients with 
Barrett’s esophagus.24 Similarly, a non-endoscopic esophageal 
sampling technique coupled to a biomarker is a potential alterna-
tive which can be tested against chromoendoscopy for early de-
tection of squamous dysplasia and ESCC.The risk model can be 
used to increase pretest probability for such screening strategies, 
by selecting a particularly high risk group.
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